Significant worries have developed in the last three years as a result of the growing worldwide spread of the mosquito-borne flavivirus, Zika. Accompanying this spread has been an increase in occurrences of the deadly birth defect microcephaly, as well as Guillain–Barré syndrome in adults in many afflicted nations. There is currently no vaccine or medication for this illness; therefore, researchers wanted to create a combined strategy that gives more immediate and long-lasting protection than conventional immunization alone. A new immune-based prophylaxis/therapy method was designed and tested for antiviral effectiveness, which included the facilitated administration of a synthetic DNA consensus prME vaccination as well as DNA-encoded anti-ZIKV envelope monoclonal antibodies (dMAb). A collection of new dMAbs that were powerful against ZIKV and could be produced in serum after 24–48 hours of in vivo treatment was created.
A novel immune-based prophylaxis/therapy approach that includes the facilitated delivery of a synthetic DNA consensus prME vaccine as well as DNA-encoded anti-ZIKV envelope monoclonal antibodies was developed and evaluated for antiviral efficacy (dMAb). This method of fast and long-term protection overcomes the limitations of standard active vaccination or passive immunotherapy. After 24–48 hours of in vivo therapy, a collection of novel dMAbs that were effective against ZIKV and could be generated in serum was developed.